Enlivex Therapeutics Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.000
-0.010 (-0.99%)
At close: Nov 7, 2025, 4:00 PM EST
0.9820
-0.0180 (-1.80%)
After-hours: Nov 7, 2025, 6:02 PM EST
Enlivex Therapeutics Employees
Enlivex Therapeutics had 71 employees as of December 31, 2021. The number of employees increased by 21 or 42.00% compared to the previous year.
Employees
71
Change (1Y)
21
Growth (1Y)
42.00%
Revenue / Employee
n/a
Profits / Employee
-$184,479
Market Cap
24.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ENLV News
- 12 days ago - Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 - GlobeNewsWire
- 5 weeks ago - D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program - GlobeNewsWire
- 2 months ago - Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results - GlobeNewsWire
- 2 months ago - Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - GlobeNewsWire
- 2 months ago - Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis - GlobeNewsWire
- 3 months ago - Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar - GlobeNewsWire
- 3 months ago - Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data - GlobeNewsWire
- 5 months ago - Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology - GlobeNewsWire